DTIL Earnings Date: Nov 2, 2026 (Estimated) — Precision BioSciences, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is DTIL's next earnings date?
Precision BioSciences, Inc. (DTIL) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.85 on revenue of $1.4M.
How did DTIL do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Precision BioSciences, Inc. posted EPS of -$1.26 versus the -$0.80 estimate, a miss of 85.3%. Revenue was $0 against a $740,000 estimate. The stock's 1-day post-earnings move was -0.7%.
How much does DTIL stock move after earnings?
DTIL beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.2% (up or down) in the day after earnings.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.80 | -1.26 | -85.29% | $0 | ❌ Miss | -0.67% | -0.67% | -1.34% |
| 2026-05-05 | Q1 2026 | -0.70 | -0.75 | -7.14% | $10.8M | ❌ Miss | -2.36% | +3.01% | -20.84% |
| 2026-03-12 | Q4 2025 | -0.47 | 1.05 | +323.40% | $34.2M | ✅ Beat | +12.06% | +38.93% | +31.82% |
| 2025-11-03 | Q3 2025 | -1.45 | -1.84 | -26.90% | $13,000 | ❌ Miss | -9.80% | -24.75% | -41.30% |
| 2025-08-07 | Q2 2025 | -1.36 | -2.13 | -56.62% | $18,000 | ❌ Miss | -4.99% | -2.49% | +5.41% |
| 2025-03-26 | Q4 2024 | -2.94 | -2.22 | +24.49% | $638,000 | ✅ Beat | -11.00% | -11.79% | +8.05% |
| 2024-11-04 | Q3 2024 | -1.92 | -2.25 | -17.19% | $576,000 | ❌ Miss | -8.09% | -7.10% | -31.15% |
| 2024-08-01 | Q2 2024 | -1.50 | 4.67 | +411.33% | $49.9M | ✅ Beat | +0.42% | -9.86% | +10.70% |
Showing last 8 quarters.